{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:53:47Z","timestamp":1779317627556,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To demonstrate the relationships between hypoglycaemia, body mass index (BMI) and quality of life, and to examine the impact of dapagliflozin on patient\u2010reported treatment satisfaction in patients with type 1 diabetes mellitus (T1DM), using data from the DEPICT (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) clinical trial programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A two\u2010stage modelling approach, using a linear regression framework, was adopted to evaluate the relationship between hypoglycaemia, BMI and quality of life. Hypoglycaemia fear score (HFS) was modelled as a function of hypoglycaemic events (non\u2010severe documented symptomatic and severe) and, subsequently, quality of life (as measured by the EQ\u20105D questionnaire) was modelled as a function of HFS and BMI. A linked evidence approach correlated the relationship between treatment, hypoglycaemic events and glycated haemoglobin (HbA1c), to the relationships captured within the regression models. The proportion of patients achieving increased patient\u2010reported treatment satisfaction, as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) total score, was compared between study arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Incident severe hypoglycaemia was associated with significantly higher HFS (coefficient estimate [CE] 14.62,\n                      <jats:italic>P<\/jats:italic>\n                      =0.004). The frequency of symptomatic hypoglycaemic events was associated with a significantly higher HFS (log transposed, CE 1.32,\n                      <jats:italic>P<\/jats:italic>\n                      =0.026). Higher HFS and higher BMI were both independently associated with a significantly lower EQ\u20105D score (HFS: CE \u20130.0024,\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001; BMI: CE \u20100.0026,\n                      <jats:italic>P<\/jats:italic>\n                      =0.016). Significantly higher proportions of dapagliflozin\u2010treated patients achieved \u22653\u2010point increases in DTSQ total score compared to patients in the placebo group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study demonstrated that increases in hypoglycaemia and BMI were associated with reduced quality of life in people with T1DM. Dapagliflozin\u2010treated patients achieved a reduction in HbA1c whilst avoiding an increase in hypoglycaemic events. The results also showed that treatment with dapagliflozin was associated with an improvement in treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13972","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T23:54:44Z","timestamp":1579737284000},"page":"857-865","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-742X","authenticated-orcid":false,"given":"Jason","family":"Gordon","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Beresford\u2010Hulme","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Bennett","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjeet","family":"Tank","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Edmonds","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-9058","authenticated-orcid":false,"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411243312107"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1245"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1902"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12030"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0748"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0129"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-86"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0157-z"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12689"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-88"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-73"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03078.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.5604\/12321966.1141381"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02956.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","unstructured":"TorjesenI.Diabulimia: the world's most dangerous eating disorder.2019;364:1982.","DOI":"10.1136\/bmj.l982"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S58813"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.01.002"},{"issue":"2","key":"e_1_2_7_21_1","first-page":"91","article-title":"Quality of life and fear for hypoglycaemia in patients with type 2 diabetes mellitus","volume":"215","author":"Jodar\u2010Gimeno E","year":"2015","journal-title":"Rev Clin Esp."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0712-x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00260.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S062"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0623"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1343"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"e_1_2_7_32_1","first-page":"111","volume-title":"Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice","author":"Bradley C","year":"1994"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04480.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.03.019"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.10.010"},{"key":"e_1_2_7_36_1","unstructured":"USFoodandDrugAdministration.Sotagliflozin for the treatment of type 1 diabetes. 2018. https:\/\/www.fda.gov\/media\/121285\/download. Accessed September 2 2019."},{"key":"e_1_2_7_37_1","unstructured":"European Medicines Agency. Forxiga : EPAR \u2010 medicine overview. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forxiga\u2010epar\u2010medicine\u2010overview_en.pdf. Accessed September 2 2019."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13972","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:41:18Z","timestamp":1761892878000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/dom.13972"],"URL":"https:\/\/doi.org\/10.1111\/dom.13972","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2019-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}